AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03985514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic treatment (Piperacillin/Tazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3).
Description: Intravenous antibiotic treatment x 3, followed by oral antibiotics for 8-10 Days.
Study NCT03985514 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active observation
Description: In-hospital observation without antibiotics
Study NCT00450333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dynepo (Epoetin delta)
Description: subcutaneous, BIW for 24 weeks
Study NCT00450333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dynepo
Description: subcutaneous, QW for 24 weeks
Study NCT00450333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dynepo
Description: subcutaneous, Q2W for 24 weeks
Study NCT01927666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100mg glucoraphanin
Description: The extent of ITC excretion in urine from a capsule delivered dose of glucoraphanin
Study NCT01601782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Scan
Description: Subject will be required to lie flat for no longer than 3 minutes to complete a volume imaging ultrasound scan of the injured area. Following the volume imaging scan a conventional ultrasound scan will be completed as ordered by their clinician.
Study NCT01601782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Scan using a General Electric Ultrasound Scanner Model Logiq E9 (model name).
Description: The subject will be required to lie flat for approximately 5 to 10 minutes to complete a conventional ultrasound scan to x-ray the muscle and tendon injuries.
Study NCT01622972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethyleneglycol
Description: Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.
Study NCT04265781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Three different doses over the course of study
Study NCT01716975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm 3
Study NCT04265781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo to BAY1817080
Study NCT04489329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ingestible Capsule
Description: Participants will swallow capsule and undergo X-rays to establish transit
Study NCT04489329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Participants will swallow a probiotic capsule and the sample collection capsule at the same time to establish concentration of strain in small intestine.
Study NCT02028741 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transverse vertebral pressures
Description: Graded transverse mobilization directed to the thoracic spine
Study NCT02028741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transverse vertebral pressures
Description: Graded transverse mobilization directed to the thoracic spine
Study NCT02853578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busonid (budesonide 200mcg and 400mcg)
Description: cartridge containing 60 tablets of 200 mcg or 400 mcg and an inhaler;~1 application (inhalation) of 200mcg every 12 noon (400 mcg / day). During the visits of monitoring (V1 and V2) the doctor in charge assess the need to increase the dose of PSI 400mcg for every 12 hours (800mcg / day); treatment for 12 weeks.
Study NCT01352780 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Motivational interviewing
Description: Motivational interviewing technique will be used to improve patient adherence to multiple health behaviour changes and support patients with psoriasis to self- manage effectively. The intervention will discuss on four main topics: diet, physical activity, stress management and psoriasis treatment.~Motivational interviewing is a patient centered directive counselling technique that focuses on assisting patients to identify their problems and involves exploring ambivalence in an empathic manner. A key goal in motivational interviewing is to increase the importance of change from the client's perspective. This is accomplished by using specific types of open ended questions, selective reflections and reflective listening.
Study NCT01772212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg
Description: Test product
Study NCT01326689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2246
Description: Rescue medication at an optimal dose, which is determined by dose titration
Study NCT01326689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01772212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg
Description: Reference product
Study NCT01131923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine Tablets, 10 mg
Study NCT01131923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine Tablets, 10 mg
Study NCT00671502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisoprodol SR
Description: 700 mg twice daily
Study NCT00671502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisoprodol SR
Description: 500 mg twice daily
Study NCT00671502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT03736291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) is a widely used non-invasive neuromodulation technique that induces excitatory changes in the cerebral cortex stimulated by repeated pulsed magnetic fields on the scalp.
Study NCT03736291 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) is a widely used non-invasive neuromodulation technique that induces excitatory changes in the cerebral cortex stimulated by repeated pulsed magnetic fields on the scalp.
Study NCT01106898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01106898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT01106898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT01106898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02466113 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A classic stratified tool
Description: Investigators randomly assign patients to be assessed by by classical pathological features. Pathological features include poorly differentiated histology(exclusive of those cancers that are MSI-H),lymphatic/vascular invasion,bowel obstruction and \<12 lymph nodes examined. Investigators defined high risk patient if they had any pathological features, the others as low risk patient. The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
Study NCT00999791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Study NCT00999791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Study NCT00732355 — intervention group
Intervention type: DEVICE
Intervention: Syph-Check POC
Description: Rapid membrane test for syphilis antibodies
Study NCT03313284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RMT
Description: RMT consists of six bouts of 5-min of volitional hyperpnoea . After each RMT bout, participants will breathe room air for 5 minutes.
Study NCT03313284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RMT + IH
Description: RMT and IH consist of six bouts of 5-min of volitional hyperpnoea. After each RMT bout, participants will breathe a hypoxic gas mixture (10.5% O2 ) for 5 minutes.
Study NCT03313284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention
Study NCT04583202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exposure to placebo
Description: Patients are exposed to a placebo for 4h in the Alyatec EEC
Study NCT04583202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to allergen
Description: Patients are exposed to birch pollen allergens for 4h in the Alyatec EEC
Study NCT00825396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-KAD Ophthalmic Solution
Description: 4 drops applied daily for 150 days
Study NCT01437176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new type of intramedullary nail
Description: This is a new fixation treat for intertrochanteric fracture.
Study NCT01437176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The intramedullary nail of PFNA
Description: It was used very common in treat with intertrochanteric fracture.
Study NCT03255538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DFM: Mean pressure
Description: Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment.
Study NCT03255538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DFM: Mean pressure - 25%
Description: Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment decremented by 25%.
Study NCT03255538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DFM: Mean pressure + 25%
Description: Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment incremented by 25%.
Study NCT03417362 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Animation
Description: 3 minute video describing and explaining early medical abortion, followed by questionnaire
Study NCT01688843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INGEVITY lead
Study NCT01253265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2439821
Description: Administered subcutaneously
Study NCT01253265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study NCT00769717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness-Centered (HUGS)
Description: A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
Study NCT00769717 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight-Centered (LEARN)
Description: The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
Study NCT03287570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cettum
Description: The treatment is applied twice a week for 15 minutes for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Electric moxibustion, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea) is used.
Study NCT03287570 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional indirect moxibustion
Description: The treatment is applied twice a week for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Traditional indirect moxibustion, Taekeukttum manufactured by Haenglim Seowon Medical Co.(China) is used. A total of three moxibustion cones are applied indirectly to each point per treatment session.
Study NCT03287570 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The patients in this group maintain the usual treatment and self-care.
Study NCT00435812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV and/or Placebo
Description: Intramuscular (IM) injections on Week 0, Week 4; placebo (saline) injection at Week 24
Study NCT00435812 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Intramuscular (IM) injections on Week 0, Week 4, and Week 24
Study NCT03689803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: sleeve gastrectomy.
Study NCT03689803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric bypass
Description: gastric bypass
Study NCT02649907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional stimulation via different testmeals
Description: nutritional stimulation of hormonal response through different testmeals
Study NCT02649907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: nutritional counseling for healthy eating behaviour
Study NCT02649907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: formula diet
Description: formula diet to help weight loss
Study NCT00640445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Description: In EW, people are asked to write about their deepest thoughts and feelings surrounding a significant life event for 20 minutes a day for 4 days
Study NCT04529837 — intervention group
Intervention type: OTHER
Intervention: Gauze
Description: placement of gauze
Study NCT00640445 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Writing
Description: Those assigned to control writing conditions are asked to describe factual information for 20 minutes a day for 4 days.
Study NCT02671994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G8 screening
Study NCT02671994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric assessment
Study NCT01778829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP ventilation mode
Description: Patients are ventilated through a nasal prong coneected to a ventilator that provides a continuous positive airway pressure
Study NCT01778829 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIPPV ventilation mode
Description: Patients are ventilated through a nasal prong connected to a ventilator that provides a non synchronized intermittent positive pressure ventilation
Study NCT01306357 — intervention group
Intervention type: DRUG
Intervention: Somatropin
Description: 4 mg or 10 mg delivered by needle-free device
Study NCT03838822 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cofactors
Description: Oral administration of 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
Study NCT01382979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AlcoholEdu for College
Description: Online course for college freshmen.
Study NCT00711802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Study NCT00711802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Study NCT02425800 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of tissue samples
Study NCT02425800 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00023543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet, fat-restricted
Description: Reduction in total, saturated, trans fat, cholesterol, calories. Increase in fiber. Promotion of nutrient-dense, high-volume, low calorie foods.
Study NCT00023543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Rigorous, stepped care approach to reach 150 min/week of physical activity.
Study NCT00227162 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group 1
Description: Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive positive affect intervention.
Study NCT00751283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GRST Peripheral Catheter System
Description: Treatment to dilate stenoses and reduce plaque in treated vessels
Study NCT00227162 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive the self-affirmation intervention.
Study NCT00882908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.
Study NCT00227162 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group 3
Description: Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive both positive affect and self-affirmation intervention.
Study NCT03444519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: This drug is in our routine use of neuroanesthesia, are given for facilitate brain relaxation
Study NCT03444519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: This drug is in our routine use of neuroanesthesia, are given for facilitate brain relaxation
Study NCT04529837 — intervention group
Intervention type: OTHER
Intervention: No gauze
Description: no gauze
Study NCT01307111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.
Study NCT01307111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pills which are identical to the study drug in appearance, taste, and smell.
Study NCT04573907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Levothyroxine 100 mcg
Description: Administration of a 600 mcg levothyroxine dose
Study NCT04573907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Eutirox 100 mcg
Description: Administration of a 600 mcg levothyroxine dose
Study NCT00681655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol (6% in saline vehicle) infused for 2.8 hour long clamping session (Breath alcohol level maintained at 60 mg/dL throughout).
Study NCT00681655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (saline vehicle) infused for 2.8 hour long session.
Study NCT04034407 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Damage control surgery
Description: All patients with clinical and radiological suspicion of colonic perforation and generalized Peritonitis with indication for emergency surgery were included in the study.~Randomisation was performed intraoperatively in all patients after the performing surgeon confirmed a colonic perforation with generalized peritonitis.
Study NCT04034407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Damage control surgery
Description: All patients with clinical and radiological suspicion of colonic perforation and generalized Peritonitis with indication for emergency surgery were included in the study.~Randomisation was performed intraoperatively in all patients after the performing surgeon confirmed a colonic perforation with generalized peritonitis.
Study NCT04234321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basic fibroblast growth factor
Description: Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.
Study NCT04234321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kangfuxin Liquid
Description: Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.